Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products

被引:121
|
作者
Fernando, Dinali H. [1 ]
Forbes, Josephine M. [2 ]
Angus, Peter W. [3 ]
Herath, Chandana B. [1 ]
机构
[1] Univ Melbourne, Dept Med, Melbourne, Vic 3084, Australia
[2] Univ Queensland, Mater Inst, Brisbane, Qld 4102, Australia
[3] Austin Hlth, Liver Transplant Unit, Heidelberg, Vic 3084, Australia
基金
英国医学研究理事会;
关键词
advanced glycation end products; hepatic Kuppfer cells; hepatic stellate cells; non-alcoholic fatty liver disease; oxidative stress; receptor for advanced glycation end products; HEPATIC STELLATE CELLS; OXIDATIVE STRESS; KUPFFER CELLS; MEDITERRANEAN DIET; ELEVATED LEVELS; RECEPTOR; RAGE; ACTIVATION; INFLAMMATION; ENDPRODUCTS;
D O I
10.3390/ijms20205037
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Non-alcoholic fatty liver disease (NAFLD) affects up to 30% of the adult population and is now a major cause of liver disease-related premature illness and deaths in the world. Treatment is largely based on lifestyle modification, which is difficult to achieve in most patients. Progression of simple fatty liver or steatosis to its severe form non-alcoholic steatohepatitis (NASH) and liver fibrosis has been explained by a 'two-hit hypothesis'. Whilst simple steatosis is considered the first hit, its transformation to NASH may be driven by a second hit. Of several factors that constitute the second hit, advanced glycation end products (AGEs), which are formed when reducing-sugars react with proteins or lipids, have been implicated as major candidates that drive steatosis to NASH via the receptor for AGEs (RAGE). Both endogenous and processed food-derived (exogenous) AGEs can activate RAGE, mainly present on Kupffer cells and hepatic stellate cells, thus propagating NAFLD progression. This review focuses on the pathophysiology of NAFLD with special emphasis on the role of food-derived AGEs in NAFLD progression to NASH and liver fibrosis. Moreover, the effect of dietary manipulation to reduce AGE content in food or the therapies targeting AGE/RAGE pathway on disease progression is also discussed.
引用
收藏
页数:19
相关论文
共 50 条
  • [31] Role of ezetimibe in non-alcoholic fatty liver disease
    Filippatos, Theodosios D.
    Elisaf, Moses S.
    WORLD JOURNAL OF HEPATOLOGY, 2011, 3 (10) : 265 - 267
  • [32] The Role of Non-Alcoholic Fatty Liver Disease in Infections
    Krznaric, Juraj
    Vince, Adriana
    LIFE-BASEL, 2022, 12 (12):
  • [33] The Role of Cytokines in Non-Alcoholic Fatty Liver Disease
    Tilg, Herbert
    DIGESTIVE DISEASES, 2010, 28 (01) : 179 - 185
  • [34] Role of hepatokines in non-alcoholic fatty liver disease
    Ke, Yini
    Xu, Chengfu
    Lin, Jin
    Li, Youming
    JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE, 2019, 7 (04) : 143 - 148
  • [35] Role of mitochondria in non-alcoholic fatty liver disease
    Pessayre, Dominique
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2007, 22 : S20 - S27
  • [36] Role of ezetimibe in non-alcoholic fatty liver disease
    Theodosios D Filippatos
    Moses S Elisaf
    World Journal of Hepatology, 2011, 3 (10) : 265 - 267
  • [37] Role of nutrition in non-alcoholic fatty liver disease
    Peter, Szabolcs
    Weber, Peter
    ANNALS OF NUTRITION AND METABOLISM, 2015, 67 : 91 - 91
  • [38] The Role of Fucoxanthin in Non-Alcoholic Fatty Liver Disease
    Winarto, Jessica
    Song, Dae-Geun
    Pan, Cheol-Ho
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (09)
  • [39] The role of elastography in non-alcoholic fatty liver disease
    Liguori, Antonio
    Ainora, Maria E.
    Riccardi, Laura
    De Matthaeis, Nicoletta
    Pizzolante, Fabrizio
    Gasbarrini, Antonio
    Zocco, Maria A.
    Grieco, Antonio
    Rapaccini, Gianludovico
    Miele, Luca
    MINERVA GASTROENTEROLOGY, 2021, 67 (02): : 164 - 170
  • [40] Role of Leptin in Non-Alcoholic Fatty Liver Disease
    Jimenez-Cortegana, Carlos
    Garcia-Galey, Alba
    Tami, Malika
    del Pino, Pilar
    Carmona, Isabel
    Lopez, Soledad
    Alba, Gonzalo
    Sanchez-Margalet, Victor
    BIOMEDICINES, 2021, 9 (07)